The Worldwide Circulating Tumor Cell Diagnostics Industry is Expected to Reach $1.9 Billion by 2028

DUBLIN, March 3, 2022 /PRNewswire/ -- The "Circulating Tumor Cell Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

The global circulating tumor cell (CTC) diagnostics market is projected to reach US$ 1,909.41 million by 2028 from US$ 3,656.38 million in 2021; it is expected to grow at a CAGR of 9.7% during 2021-2028. The market growth is mainly attributed to the increasing prevalence of cancer globally.

A circulating tumor cell (CTC) is a cell that sheds into lymphatics from the primary tumor and carried out throughout the body with blood circulation. Circulating tumor cells are the seeds for growth and metastases for additional tumors in distant organs and is responsible for majority of cancer-related deaths. The diagnosis, detection, and analysis of CTC can assist in patients' prognoses determine appropriate tailored treatments for the patients. The CTC diagnosis has a lot of advantages for traditional diagnostic procedures. It is a noninvasive and effective process that can be used repeatedly. CTC detection and enrichment, CTC direct detection, and CTC analysis are among the major technologies.

Health systems across the globe are witnessing a substantial increase in the prevalence of cancer. According to the World Health Organization, cancer is the second-leading cause of mortality worldwide. The global cancer burden has increased to 19.3 million cases and 9.96 million cancer deaths by 2020, according to the International Agency for Research on Cancer (IARC).

According to a study published by the National Cancer Institute, cancer incidence in the US is likely to reach 1.9 million in 2021. Around 0.6 million people were anticipated to die in 2021 in the US due to cancer. Moreover, according to data published by Cancer Research UK in 2020, around 0.16 million people in the UK die each year due to cancer. As per the Globocan report, in 2018, there were 911,014 breast cancer cases and 310,577 deaths due to breast cancer, of which 367,900 and 162,468 breast cancer cases were reported in China and India, respectively. Thus, the increased prevalence of cancer across the globe is propelling the demand for circulating tumor cell diagnostics.

The analysis and detection of circulating tumor cells assist in early patient diagnosis and prognosis help determine accurate treatment for the patient. The CTC diagnostics are used in various types of cancers, including prostate cancer, breast cancer, colorectal cancer, kidney cancer, lymphomas, lung cancer, and melanoma. There has been a high demand for CTC diagnostics in recent years due to its reliability and accuracy in identifying the risk of various cancers and monitoring different cancer treatments.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the circulating tumor cell (CTC) diagnostics market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global circulating tumor cell (CTC) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

2. Key Takeaways

3. Research Methodology

4. Circulating Tumor Cell (CTC) Diagnostics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South and Central America PEST Analysis
4.3 Experts Opinion

5. Circulating Tumor Cell (CTC) Diagnostics Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer Globally
5.1.2 Rising Demand for Minimally Invasive Diagnostic Procedures
5.2 Market Restraints
5.2.1 Rising Dearth of Skilled Professionals Performing Diagnostic Procedures
5.3 Market Opportunities
5.3.1 Untapped Potential of Emerging Economies
5.4 Future Trends
5.4.1 Technological Advancements in Isolation of Circulating Tumor Cell
5.5 Impact Analysis

6. Circulating Tumor Cell (CTC) Diagnostics Market- Global Analysis
6.1 Global Circulating Tumor Cell (CTC) Diagnostics Market Revenue Forecast and Analysis
6.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Revenue Forecast and Analysis
6.3 Market Positioning of Key Players

7. Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts To 2028 - Technology
7.1 Overview
7.2 Global Circulating Tumor Cell (CTC) Diagnostics Market, By Technology, 2021 & 2028 (%)
7.3 CTC detection and Enrichment Method
7.3.1 Overview
7.3.2 CTC detection and Enrichment Method: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 CTC Direct Detection Method
7.4.1 Overview
7.4.2 CTC Direct Detection Method: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.5 CTC Analysis
7.5.1 Overview
7.5.2 CTC Analysis: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

8. Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts To 2028 - Application
8.1 Overview
8.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Share by Application - 2021 & 2028 (%)
8.3 Clinical/Liquid Biopsy
8.3.1 Overview
8.3.2 Clinical/Liquid Biopsy: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.3.3 Risk Assessment
8.3.3.1 Overview
8.3.3.2 Risk Assessment : Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.3.4 Screening and Monitoring
8.3.4.1 Overview
8.3.4.2 Screening and Monitoring: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 Research
8.4.1 Overview
8.4.2 Research: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4.2.1 Cancer Stem Cell & Tumorigenesis Research
8.4.2.1.1 Overview
8.4.2.1.2 Cancer Stem Cell & Tumorigenesis Research: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4.2.2 Drug/Therapy Development
8.4.2.2.1 Overview
8.4.2.2.2 Drug/Therapy Development: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9. Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecasts To 2028 - End user
9.1 Overview
9.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Share by End user - 2021 & 2028 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Research and Academic Institutes
9.4.1 Overview
9.4.2 Research and Academic Institutes: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Diagnostic Centers
9.5.1 Overview
9.5.2 Diagnostic Centers: Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

10. Global Circulating Tumor Cell (CTC) Diagnostics Market - Geographic Analysis

11. Impact of COVID-19 Pandemic on Global Circulating Tumor Cell (CTC) Diagnostics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Circulating Tumor Cell (CTC) Diagnostics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview

13. Company Profiles
13.1 THERMO FISHER SCIENTIFIC INC
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 STEMCELL Technologies Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 QIAGEN
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Precision Medicine Group, LLC
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 ADVANCED CELL DIAGNOSTICS, INC. (BIO-TECHNE CORPORATION)
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 EPIC SCIENCES, INC
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 SCREENCELL
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 IKONISYS, INC
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 IVDiagnostics
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 FLUXION BIOSCIENCES
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/55i0r0

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets